To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
Scientific result | Vaccine | Bacteria
In an article published in PLoS Neglected Tropical Diseases, SPI researchers show for the first time, in a mouse model, the induction of cross-protection against Salmonella and Shigella infections, two pathogenic bacteria responsible for gastrointestinal diseases (typhoid, dysentery among others) one of the main causes of morbidity and mortality, particularly in children under 5 years old, in several regions of Africa and Asia.
With a view to developing broad-spectrum vaccines capable of simultaneously protecting against these two bacterial pathogens, researchers at SPI/LERI have focused on the system that allows Salmonella and Shigella to inject their virulence factors through the plasma membrane of host cells. Their XXS-size "syringe", called type III secretion system or injectisome, is very similar. In particular, the injection needle cap proteins (SipD for Salmonella and IpaD for Shigella) have quite similar assembly mechanisms and three-dimensional structures, despite relatively weak sequence identity (38%). Moreover, their protective efficacy against each of the bacterial genera has already been demonstrated in rodents. These elements led the researchers to consider the possibility of obtaining cross-protection against Salmonella and Shigella using SipD or IpaD as immunogens. The team administered each of the two proteins, alone, by intranasal or intragastric routes in a mouse model of intestinal infection. Strong humoral responses (production of immunoglobulins G and A) were induced against both proteins regardless of the route of administration. In addition, mice immunized with SipD or IpaD were protected against infection by Salmonella enterica (serovar Typhimurium) or Shigella flexneri. The study thus shows that cross-protection against Salmonella - Shigella is possible and paves the way for the development of broad-spectrum therapeutic molecules.
Stéphanie Simon (email@example.com)
Bakhos Jneid, Audrey Rouaix, Cécile Féraudet-Tarisse, Stéphanie Simon. SipD and IpaD induce a cross-protection against Shigella and Salmonella infections. | PLoS Neglected Tropical Diseases, May 2020.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.